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MBNL142 and MBNL143 gene isoforms, overexpressed
in DM1-patient muscle, encode for nuclear proteins
interacting with Src family kinases
A Botta1,9, A Malena2,9, E Tibaldi3, L Rocchi1, E Loro2,4, E Pena2, L Cenci5, E Ambrosi5, MC Bellocchi1, MA Pagano3, G Novelli6,
G Rossi1, HL Monaco5, E Gianazza7, B Pantic8, V Romeo2, O Marin8, AM Brunati3 and L Vergani*,2
Myotonic dystrophy type-1 (DM1) is the most prevalent form of muscular dystrophy in adults. This disorder is an RNA-dominant
disease, caused by expansion of a CTG repeat in the DMPK gene that leads to a misregulation in the alternative splicing of pre-
mRNAs. The longer muscleblind-like-1 (MBNL1) transcripts containing exon 5 and the respective protein isoforms (MBNL142–43)
were found to be overexpressed in DM1 muscle and localized exclusively in the nuclei. In vitro assays showed that MBNL142–43
bind the Src-homology 3 domain of Src family kinases (SFKs) via their proline-rich motifs, enhancing the SFK activity. Notably,
this association was also confirmed in DM1 muscle and myotubes. The recovery, mediated by an siRNA target to Ex5-MBNL142–43,
succeeded in reducing the nuclear localization of both Lyn and MBNL142–43 proteins and in decreasing the level of tyrosine
phosphorylated proteins. Our results suggest an additional molecular mechanism in the DM1 pathogenesis, based on an altered
phosphotyrosine signalling pathway.
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Myotonic dystrophy type-1 (DM1, OMIM 160900) is an
autosomal dominant multisystemic disorder with considerable
phenotypic variation between individuals; clinical aspects
include myotonia, progressive muscle weakness, cataracts,
insulin resistance and cardiac conduction defects.1 The
genetic mutation responsible for DM1 is an expanded (CTG)n,
in the 30-untranslated region (UTR) of the dystrophia
myotonica protein kinase (DMPK) gene (OMIM 605377), on
chromosome 19q13.2–4 DM1 pathogenesis is linked to the
expression of expanded mutant RNA transcripts, which
accumulate in the nuclei to form nuclear foci (ribonuclear
inclusions).5 This clue prompted the theory that a toxic
gain-of-function effect, resulting from these inclusions, alters
the proportion-activity of two RNA-binding proteins: muscle-
blind-like-1 (MBNL1) and CUG-BP1. The splicing of several
MBNL1 and CUG-BP1 pre-mRNA targets is subsequently
severely altered in DM1-affected tissues. The disruption of the
Mbnl1 gene in transgenic mouse models in fact recapitulates
the splicing abnormalities of DM1 patients,6–8 as well as the
myotonic-dystrophy-like phenotype, with skeletal muscle
myotonia and cataracts. Moreover, the myotonic-dystrophy-
like phenotype of mice expressing (CUG)n can be reversed by
overproduction of MBNL1,9 and long-term MBNL1 over-
expression prevents CUG-induced myotonia, myopathy and
alternative splicing abnormalities in DM1 mice.10 MBNL1 is
also sufficient to largely abolish DM1 foci in vivo.11 In humans,
the MBNL1 gene contains 12 exons and the coding sequence
is distributed over 10 exons (numbered 1 to 10 in this paper;
Figure 1a). The inclusion/exclusion of exons 3, 5, 7 and 9
generates several mRNA isoforms12,13 developmentally
regulated and reportedly altered in DM tissues.7,9,14,15
MBNL1 exons encode for protein domains with different
functions: exons 1, 2 and 4 are essential for RNA binding,16
exons 5 and 6 for controlling the nuclear localization of
MBNL1; exon 3 strongly enhances the affinity of MBNL1 for its
pre-mRNA target sites; exons 3 and 6 encode for a splicing
regulatory domain; and exon 7 enhances MBNL1 self-
dimerization.17 Although MBNL1 isoforms have been partly
characterized in human skeletal muscle, recent work on
DM1-patient brain revealed the existence of a combination of
foetal and adult isoforms, with the expression of additional,
longer variants assuming different functional roles (still
unexplored).9,15 The MBNL1 protein contains three proline-
rich motifs (PRMs), known to bind Src-homology 3 (SH3)
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domains present in many signalling proteins (Supplementary
Figure SF1). This observation suggests that the different
MBNL1 isoforms might regulate the activity and/or localization
of the tyrosine (Tyr) kinases of the Src family (SFKs),
triggering a signalling cascade mediated by Tyr phosphorylation.
Interestingly, CUG-BP1 was also recently found hyperpho-
sphorylated in DM1 tissues and in a DM1 mouse model.18
Intracellular localization, regulation of the alternative splicing
of model pre-mRNA, ability to interact with SFKs through SH2
and SH3 domains and susceptibility to Tyr phosphorylation of
MBNL1 isoforms in DM1 muscle and myotubes were the
aspects specifically addressed by our investigation.
Results
MBNL142–43 isoforms are overexpressed in the muscle
from DM1 patients compared with controls, and localize
in the nuclei. The complete splicing pattern of the MBNL1
gene was first determined in muscle tissues from DM1 (n¼ 8)
patients compared with controls (n¼ 4), by RT-PCR analysis.
The number assigned to each MBNL1 exon varies in the
literature; here, we use the exon numbering of Pascual and
co-workers19 and coding exons have been labelled from 1 to
10 (Figure 1a). Five major MBNL1 transcripts were identified;
their relative expression in DM1 and control samples was
found to be significantly different. The major transcripts
expressed in the muscle from controls corresponded to
MBNL140 (NM 207292.1) and MBNL141 (NM 021038.3)
isoforms. We also identified and characterized a novel
MBNL1 isoform lacking exons 5, 7 and 8 – named MBNL137L
– in view of the predicted molecular weight (MW) of the
encoded protein (Figure 1a). In the DM1 muscle, in addition
to these MBNL1 transcripts, we observed higher levels of the
MBNL142 (NM 207293.1) and MBNL143 isoforms (Figure 1b),
whereas the expression of MBNL143 and MBNL142 was
absent and greatly reduced, respectively, in the control
Figure 1 Qualitative and quantitative expression analysis of the major MBNL1 isoforms expressed in the muscle from DM1 patients and controls. (a) Representation of the
MBNL1 gene and major muscle transcripts identified in this study. The human MBNL1 gene contains 10 coding exons, represented as white boxes; untranslated regions
(UTRs) are shown in grey, and introns as lines. The names of each isoform and the exon order are indicated on the right following Pascual et al.19 (b) Representative gel
electrophoresis of the RT-PCR products corresponding to the entire coding sequences of the MBNL1 gene. Five major muscular transcripts were identified
(MBNL137L–40–41–42–43) that showed relative expression differences between four DM1 (lanes 2–5) and four control (lanes 6–9) muscle samples. (c and d) Results from Syber
Green Real Time PCR analysis using primers allowing detection of MBNL1 isoforms (c) including (Ex5-MBNL142-43) and (d) not including (DEx5-MBNL140-41) exon 5 in
muscle from DM1 (n=8, grey bars). DM1 samples express significantly higher level of Ex5-MBNL142–43 isoforms compared with controls (Po0.01 by Mann–Whitney test),
whereas no differences were found inDEx5-MBNL137L–40–41 transcript expression. All experiments were in triplicate; the median value of controls was set as one, and the level
of b-actin transcript was used for sample normalization
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muscle. The MBNL143 mRNA is expressed in human foetal
brain and mouse skeletal muscle9,15 and corresponds to the
MBNL142 sequence of Pascual’s classification with the
addition of exon 7 (Figure 1a). RT-PCR analysis, using
primers designed to discriminate between MBNL1
isoforms containing (Ex5-MBNL142–43) or not containing
(DEx5-MBNL37L–40–41) exon 5, confirmed that DM1 tissues
express higher levels of Ex5-MBNL142–43 mRNAs than
controls. Ex5-MBNL142–43 isoforms were overexpressed in
DM1 muscle 1.9- to 17.3-fold compared with controls,
whereas DEx5-MBNL137L–40–41 transcripts vary over the
range from 0.38 to 1.40 (Figures 1c and d). These results
are in accordance with the previous observation that MBNL1
autoregulates the splicing of its own pre-mRNA inducing the
exclusion of exon 5 by binding to a response element located
in intron 4 of the gene.20 The functional depletion of the
MBNL1 protein in DM1 tissues could therefore lead to the
aberrant inclusion of exon 5 within the MBNL1 transcripts.
We then subcloned the coding sequences of the
MBNL140–41–42–43 major muscular MBNL1 isoforms into
appropriate expression vectors to localize the encoded
proteins. The exon 5-dependent nuclear localization of the
MBNL142–43 isoforms has been reported in HeLa cells and
control myoblasts.15,17 Consistently, in DM1 myoblasts, the
localization of MBNL140–41-V5 isoforms was diffuse in the
cytosol and nucleus, whereas MBNL142–43-myc isoforms
were exclusively nuclear (Figure 2a), with no differences
between DM1 and control primary myoblasts (Figure 2a).
This observation suggests that in this in vitro model, the
MBNL1 cell localization is unaffected by the expression of the
pathological CUG expansions. Two novel anti-MBNL1-
specific antibodies (anti-P9 and -P11) were synthesized to
distinguish the MBNL1 isoforms. Anti-P9, targeted to the 18
amino acids encoded by exon 5, was designed to recognize
only the MBNL142–43 isoforms, whereas anti-P11, designed
against the constitutive exon 6, binds to all isoforms (see
Supplementary Figures S1 and S2). Immunofluorescence
analysis showed that the antibody anti-P9 (MBNL142–43)
colocalizes with the ribonuclear foci of DM1 muscle, as well
as the anti-P11 antibody (MBNL140–41–42–43) (Figure 2b).
However, the immunofluorescence signal of anti-P11
antibody revealed a nuclear and cytosolic expression,
providing further evidence of a ubiquitous cell distribution of
MBNL140–41 (Figure 2b). Consistent with the results of
mRNA expression, western blotting (WB) analysis showed
significant increase (Po0.01) of the signal recognized by the
anti-P9 antibody (target to exon 5) in DM1 muscle nuclei, as
compared with controls, but was absent in the cytoplasmic
fraction of all tested samples (Figures 2c and d). Tests were
performed to establish the extent to which the various
MBNL1 isoforms differed in function, properties and interac-
tions. Minigene assays on the cardiac troponin T (c-TNT) and
insulin receptor (IR) pre-mRNAs splicing21,22 revealed no
differences in the in trans regulatory splicing properties of the
characterized MBNL1 isoforms (Supplementary Figure S3).
MBNL142–43 proteins interact with SFKs, enhance cellular
Tyr phosphorylation and induce the nuclear translocation
of Lyn Tyr kinase. The four above MBNL1 isoform
sequences exhibit three PRMs, encoded by MBNL1 exon 2
(111PLQPVP116), exon 3 (161PGVPVP166) and exon 6
(295PPLPKRP301 of MBNL142–43 proteins, corresponding to
amino acids 277–283 in MBNL140–41 proteins), respectively
(Supplementary Material and Supplementary Figure S1);
these sequences display the consensus motif for interaction
with the SH3 domain within the SFKs. As the PRM binding to
the SH3 domain of SFKs is described to bring about
activation,23 turnover24 and subcellular localization25,26 of
SFKs themselves, we wondered whether the MBNL1
isoforms could affect these SFK properties, and/or whether
Lyn could be implicated in the pathogenesis of DM1. SFKs
are non-receptor Tyr kinases, classifiable into two groups,
based on the phylogenetic tree,27 namely Src-related
(Src, Yes, Fyn and Fgr) and Lyn-related SFKs (Lyn, Hck,
Lck and Blk).28 Their common modular structure consist of
(i) an N-terminal SH4 domain for acylation; (ii) the
aforementioned SH3 domain; (iii) an SH2 domain, which
recognizes phospho-Tyr (pTyr) motifs; and (iv) a kinase
domain (SH1), followed by a C-terminal tail having a
negative regulatory role when phosphorylated by the
inhibitory kinases.23 SFKs are normally maintained in a
closed, inactive conformation through two major intramo-
lecular inhibitory interactions: the binding of the phos-
phorylated C-terminal tail to the SH2 domain, and the
interaction of a polyproline type-II helical motif containing
the core sequence P–X–X–P, where X is any amino acid,
within the SH2 kinase linked with the SH3 domain.29
Conformational transition of SFKs from inactive to active
form is induced by an array of factors causing depho-
sphorylation of the C-terminal tail by several Tyr phospha-
tases and/or displacement of the SH2 or SH3 domains by
specific ligands, ultimately leading to disruption of the
inhibitory intramolecular interactions.30–34
To assess whether MBNL140–41 and MBNL142–43 inter-
acted with the SFK SH3 domain through their PRMs, we
performed competition assays by incubating the MBNL1
isoforms with Lyn or Src (the prototypical members of the two
SFK groups) in the absence or presence of a synthetic proline-
rich peptide (KGGRSRLPLPPLPPPG), which is known to
interact with Lyn SH3 domain, or the recombinant glutathione
S-transferase (GST)-Lyn SH3 domain. The following immuno-
precipitation with anti-Lyn and anti-Src antibodies showed that
only the MBNL142–43 associated with Src and Lyn via
interaction between the MBNL1 PRM and the SFK SH3
domain (Figure 3a, left panel). This interaction also deter-
mined stimulation of SFK activity (Figure 3b, right panel) and
phosphorylation of MBNL142–43 itself (Figure 3c, right panel).
Yet, denaturation by heating at 55 1C allowed MBNL140–41 to
acquire the same ability to bind to and activate Src and Lyn as
MBNL142–43 (Figures 3a and b, left panel), suggesting that the
binding motif in the latter isoforms is accessible owing to a
structural conformation conferred by the insert encoded by
exon 5. As to phosphorylation, denaturation prevented
recognition of MBNL142–43 as a substrate by Src and Lyn
(data not shown), suggesting the significance of not only the
interaction due to exposure of specific motifs but also of an
appropriate three-dimensional structure. Surface plasmon
resonance (SPR) studies confirmed the specific interaction
of the Lyn kinase SH3 domain with only MBNL143 isoform
(Supplementary Material and Supplementary Figure S4).
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Our in vitro data provide novel evidence of a strong functional
discrimination between the long and short isoforms of MBNL1
in terms of interaction with SFKs and regulation of their
activity. These novel functions of the MBNL1 proteins were
also analyzed in 293T cells co-overexpressing Lyn and one
MBNL140–41–42–43 isoform. As 293T cells express a low basal
level of SFKs, the amount of Lyn-encoding plasmid was
standardized to the expression of Lyn within HeLa cells
(Supplementary Figure S5). Figure 4a shows colocalization of
MBNL142–43 and Lyn in the nucleus, where Lyn translocated
after the overexpression of MBNL142–43 proteins, and with Lyn
being equally expressed under all the experimental conditions
and regardless of the cotransfection with MBNL1 isoforms
(Figure 4b). To assess the existence of a MBNL1/Lyn complex
Figure 2 Nuclear localization and amount of MBNL142–43 isoforms in DM1 myoblasts and muscle tissue. (a) Representative confocal images of DM1 and control primary
myoblasts, overexpressing MBNL140–41–42–43 isoforms. Immunofluorescence with specific anti-V5 (MBNL140–41) or -myc (MBNL142–43) tags was performed after 48 h. Scale
bar, 10mm. (b) Representative images of nuclear foci (red) from fixed DM1 muscle, obtained by fluorescence in situ hybridization with a Texas Red labelled (CAG)10 probe.
The MBNL1 antibodies (green) anti-P9 and anti-P11 co-localized with foci. Anti-P9 was localized only in the nucleus, in contrast with anti-P11, which was also present in the
cytosol. Scale bar, 2mm. (c) Representative WB analysis of MBNL140–41–42–43 in nuclear and cytosolic fractions from four DM1 patients and four control muscle samples.
Proteins, separated in 7.5–17.5% T30C4 SDS-PAGE gels, were blotted onto nitrocellulose and probed with anti-P9 (specific for MBNL142–43 isoforms) and anti-P11
antibodies. Lamin A/C and b-tubulin protein levels were used to normalize the samples from nuclear and cytosolic fractions, respectively. (d) The graph represents the
mean±S.D. of at least three experiments. In each lane the ratio between the signal density of MBNL142–43 (upper band) and the sum of the signal density of the two MBNL1
bands (upper and lower) was calculated. The values were expressed as percentage of the value obtained in the control muscle, considered as reference unit. **Significant
difference for Po0.01 by Mann–Whitney test
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in vivo, immunoprecipitation assays with anti-Lyn antibody on
293T cells coexpressing Lyn and each of the MBNL1 isoforms
were carried out. This experiment revealed that MBNL142–43
(but not MBNL140–41) co-immunoprecipitated with Lyn, this
event occurring as a result of PRM/SH3 domain interaction, as
confirmed by the competition assay with GST-Lyn-SH3
(Figure 4c). Moreover, the WB analysis of the nuclear fraction
of these cells highlighted that the nuclear levels of Lyn rose up
fourfold (Figure 4d, lanes 4 and 5 versus lane 1) when the
MBNL142–43 was coexpressed, whereas the localization of
Lyn remained unchanged in the presence of MBNL140–41
(Figure 4d, lanes 2 and 3 versus lane 1). To explore whether
this interaction determined SFK activation in the nuclei, as a
result of SH3 engagement by PRMs,35 WB analysis with
anti-pTyr antibody revealed a dramatic increase in Tyr
phosphorylation in the nuclear fraction of 293T cells when
MBNL142–43, and not MBNL140–41, were coexpressed with
Lyn (Figure 4e).
Figure 3 Analysis of the interaction between the SH3 domain of the SFKs Src and Lyn and the proline-rich motif of recombinant MBNL140–41 and MBNL142–43 isoforms.
(a) The interaction between SH3 domain of two SFK (Src and Lyn) and the proline-rich motifs of recombinant MBNL140–41 and MBNL142–43 isoforms. The 0.2mg of
recombinant MBNL140–41 or MBNL142–43 (as such or heated at 55 1C for 10 min, denat. MBNL1) was incubated with 0.1mg of Src or Lyn in the absence or presence,
respectively, of a proline-rich peptide or the GST-Lyn SH3 domain, for 10 min at 30 1C. Three-fourths of the sample underwent immunoprecipitation with anti-Src or anti-Lyn
antibodies, respectively. Immunocomplexes were then probed with anti-P11 or anti-P9 antibodies, and subsequently with anti-Src or anti-Lyn antibodies. The presence of
MBNL42 or MBNL43 (right panel), but not of MBNL40 or MBNL41 (left), indicates its association with the two SFKs and suggests that the stretch encoded by exon 5 might have a
role in this interaction, possibly through a conformational change that renders the PRMs available to binding. Moreover, competition assays carried out in the absence or
presence of a synthetic proline-rich peptide (50-KGGRSRLPLPPLPPPG-30) known to interact with the Lyn SH3 domain, or the GST-Lyn/SH3 domain, confirmed that this
interaction was mediated by PRMs and the SH3 domain. The remainder of the sample underwent WB analysis (lanes 7 and 8) (b) As this interaction was also a prerequisite for
enhancement of SFK activity relative to the basal state, we tested Tyr kinase activity of Src (top panel) and Lyn (bottom) on the Src-specific peptide substrate cdc2 in the absence
(lane 1) or presence of increasing concentrations of MBNL141 (left panels, lanes 2–5) and denat. MBNL141 (left panels, lanes 6–9) or MBNL143 (right panels, lanes 2–5) and
denat. MBNL143 (right panels, lanes 6–9), alternatively supplemented with the GST-Lyn SH3 domain (lanes 4 and 5, and 8–9) as described in the Materials and Methods
section. (c) As this interaction was also a prerequisite for recognition of MBNL143 as a substrate by SFKs, we tested whether MBNL141 or MBNL143 (each 1 mM) were
phosphorylated by Lyn and Src in the absence (solid triangles and solid squares, respectively) or presence (open triangles and open squares, respectively) of the GST-Lyn
SH3 domain. At various time points, reactions were stopped and the phosphate incorporated was analyzed after SDS-PAGE on the Cyclone Plus. The amount is expressed as
mol P incorporated/mol prot. (values represent the mean of three separate experiments±S.D.). As expected, only MBNL143 is phosphorylated by Src. The same set of
experiments conducted with the MBNL140 and MBNL142 isoforms demonstrated that these two proteins behave similarly to MBNL141 and MBNL143, respectively (data not
shown). Only MBNL142–43 isoforms were able to significantly increase Src and Lyn activity, suggesting a novel function of these long isoforms in kinase enzyme regulation.
Data are expressed as mean±S.D. from three separate experiments. *Po0.05; ***Po0.001 by Kruskal–Wallis analysis
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Muscle and myotubes from DM1 patients show
increased nuclear localization of Lyn and Tyr hyperpho-
sphorylation. These data strongly suggest that MBNL142–43
protein isoforms, whose abundance is elevated in DM1
muscle, might induce an inappropriate activation of Lyn in
DM1 muscle cell nuclei: as a direct test, we first examined
muscle sections from DM1 patients (n¼ 4) and controls
(n¼ 4). Confocal immunofluorescence images of the
MBNL142–43 and Lyn proteins showed a nuclear localization
of both proteins only in DM1 muscle (Figure 5a), confirmed
by Manders overlap coefficient analysis (Figure 5b).
Moreover, to assess whether the existence of an MBNL1/
Lyn complex was also present in the nuclei of muscle tissue,
co-immunoprecipitation analysis with anti-P9 (against
MBNL142–43) antibody was performed on DM1 and control
muscle samples. Consistently with the results obtained with
293T cells and in line with the increased amount of
MBNL142–43 in DM1 muscle tissue (Figures 2c–d), we found
that MBNL142–43 co-immunoprecipitated with Lyn only in the
nuclear fraction of DM1 muscles, in parallel with an increased
nuclear activity of Lyn (Figure 5c). This event occurred as a
result of PRM/SH3 domain interaction, as confirmed by the
competition assay with GST-Lyn-SH3 (Figure 5c).
The same parameters were analyzed in 15-day-
differentiated myotubes from two DM1 patients and three
controls. As expected and reported elsewhere,36 RT-PCR-
based analysis of MBNL1 splicing showed that DM1
myotubes had a statistically significant (2.8-fold) increase in
the expression of Ex5-MBNL1 transcripts relative to controls
(Figures 6a and b). Consistently, WB analysis demonstrated a
significantly increased amount of Lyn (570%, Po0.02) and
MBNL142–43 (680%, Po0.005) (Figures 6c, e and f) in the
nuclei of the same DM1 myotubes, as compared with controls.
The increased nuclear localization of Lyn in DM1 myotubes
Figure 4 Translocation of Lyn to the nuclei of 293T cells occurs only upon co-expression with MBNL142–43. (a) Representative confocal images of 293T cells co-transfected
with plasmids carrying different MBNL1 isoforms (MBNL140–41–42–43 in pEF1-Myc/HisA vector) and Lyn (pCMV6-XL4/Lyn). Nuclei were labelled with DAPI (blue), MBNL1 with
anti-P9 (MBNL142–43) or anti-P11 (MBNL140–41) antibodies (red) coupled to immunodetection of Lyn (green). Scale bar 10 mm. (b) Representative WB analysis of whole-cell
lysates from 293T cells transfected with expression vectors for Lyn, MBNL140, MBNL141, MBNL142 and MBNL143 probed with anti-Lyn antibody (top strip), anti-P11 antibody
(middle strip) and anti-P9 antibody (bottom strip). (c) Representative co-immunoprecipitation of four-fifths of whole-cell lysates from 293T cells, overexpressing MBNL141
(pEF1/MBNL141 (left panel), lanes 1 and 2), or MBNL143 (pEF1/MBNL143 (right panel), lanes 3 and 4) and Lyn (pCMV6-XL4/Lyn, lanes 1–4). Thirty-six hours after transfection,
whole-cell lysates were immunoprecipitated with anti-Lyn in the absence (lanes 1 and 3) or presence (lanes 2 and 4) of the GST-Lyn SH3 domain. The immunocomplexes and
one-fifth of the whole-cell lysates underwent WB analysis with anti-P11 or anti-P9 antibodies, respectively, and subsequently with anti-Lyn antibodies. The figure represents
one of three independent experiments. The same set of experiments conducted with MBNL140 and MBNL142 isoforms demonstrated that these two proteins behave similarly
to MBNL141 and MBNL143, respectively, again supporting the hypothesis that it is exon 5 that enables MBNL1s to interact with SFKs (data not shown). (d) Representative WB
analysis of nuclear lysates from 293T cells transfected with expression vectors for Lyn (lanes 1–5), MBNL140 (lane 2), MBNL141 (lane 3), MBNL142 (lane 4) and MBNL143
(lane 5). The membranes were probed with anti-Lyn and with anti-Lamin B antibody as loading control. The resulting bands underwent densitometric analysis. The values
(arbitrary units) represent the mean±S.D. of at least three experiments. Reference unit: lane 1 sample (only transfected with Lyn). **Significant difference for Po0.01 by
Kruskal–Wallis analysis. (e) Representative WB analysis of nuclear lysates from 293T cells, transfected with expression vectors for Lyn (lanes 1–5), MBNL140 (lane 2),
MBNL141 (lane 3), MBNL142 (lane 4) and MBNL143 (lane 5) and probed with anti-p-Tyr antibody. The membranes were reprobed with anti-Lamin B antibody as loading control
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caused a Tyr hyperphosphorylation (250%, Po0.02), as
revealed by WB analysis (Figures 6c and d). Immunofluores-
cence analysis with anti-Lyn and anti-P9 (against MBNL142–43)
antibodies in 15-day-differentiated myotubes gave further
confirmation of the MBNL142–43 and Lyn cellular distribution
in DM1 and control cells (Figure 6g), validated by Manders’
overlap coefficient analysis (Figure 6h).
siRNA-mediated downregulation of MBNL142–43 isoforms
in myotubes from DM1 patients restores cytoplasmic
localization of Lyn. We used an siRNA-mediated approach
to test whether both cytoplasmic localization of Lyn and
increased nuclear Tyr phosphorylation could be restored
in myotubes from DM1 patients. An siRNA specific to
target MBNL1-exon 5 (siMBNL1-Ex5) was designed and
tested on DM1 myotubes overexpressing Ex5-MBNL142–43
transcripts (Figure 6a). Splicing analysis, using primers
designed to discriminate between Ex5-MBNL142–43 and
DEx5-MBNL37L–40–41 isoforms, revealed a marked reduction
of MBNL142–43 (from 70 to 85%), but not of the MBNL140–41
transcripts (from 97 to 115%) (data not shown). Immuno-
fluorescence, on differentiated myotubes from DM1 patients
48 h after siRNA transfection, revealed that the signal
corresponding to MBNL142–43 isoforms decreased in the
nuclei along with that of Lyn, which instead increased almost
throughout the myotube cytoplasm (Figure 6g). These data
have been further validated by colocalization analysis,
showing the significant decrease of Manders’ overlap
coefficient in DM1 siRNA-transfected myotubes (Figure 6h)
to the control value. WB analysis confirmed the decrease in
the nuclear amount of Lyn and MBNL142–43 to 67% and 44%,
respectively, relative to the cells transfected with empty
vector (mock) (Figures 6i, k and l), in parallel with a 35%
decrease of Tyr phosphorylation (Figures 6i and j). These
results strengthen the case for a functional link between the
Ex5-containing MBNL1 isoforms and the Tyr kinase Lyn.
Discussion
MBNL1 expression is crucial in the DM pathophysiology, and
the loss of MBNL1 protein leads to the spliceopathy in the
muscle tissues of DM patients and mouse models.8,37 The
MBNL1 pre-mRNA itself undergoes tissue-specific alternative
splicing.17 In this paper, we showed that muscle tissue from
DM1 patients overexpresses MBNL142 and MBNL143
isoforms containing exon 5 (Ex5-MBNL142–43). In contrast,
control muscle showed a prevalent expression of the
MBNL140 and MBNL141 isoforms, without exon 5
(DEx5-MBNL37L–40–41). The altered splicing of the MBNL1
gene has also been reported in DM1 brain, whereas
DEx5-MBNL40–41 isoforms are expressed in adult tissues.
15
These data support the hypothesis that the DM1 phenotype is
in part due to a change in the splicing pattern linked to the
trans-dominant effect of the CUG and CCUG repeats,
resulting in the mixed expression of adult and foetal
isoforms of various proteins, including MBNL1 itself. The
overexpression of Ex5-MBNL142–43 isoforms in the muscle
from DM1 patients, ensuring their restrictive nuclear
Figure 5 The nuclear colocalization of Lyn and MBNL142–43 was detected in DM1 muscle tissues. (a) Representative images at epifluorescent (low magnification) and
confocal (high magnification) microscope of nuclei from muscle samples (four controls and four DM1 patients). The muscle sections were probed with anti-P9 (red) and anti-
Lyn (green), nuclei were marked with DAPI. Scale bar, 10 mm. (b) Quantification of Lyn and MBNL142–43 signal colocalization in control and DM1 muscle samples. Values
represent Manders’ overlap coefficient (the fraction of total fluorescence signal of Lyn overlapping with MBNL142–43 signal), obtained from confocal images of nuclear and
perinuclear regions as in (a) and as described in Materials and Methods section. Statistical significance was evaluated by two-tailed Student’s t-test (n¼ 50 nuclei,
***Po0.001). (c) MBNL142–43 immunoprecipitation from nuclear fractions, obtained from two controls and two DM1 muscle samples. Immunoprecipitate was used for Lyn Tyr
kinase activity assay (upper panel) and for WB analysis (below), in the absence or presence of binding competitor domain GST-Lyn/SH3, as described in Materials and
Methods section. Lyn co-immunoprecipitates with MBNL142–43 and displays Tyr kinase activity only in DM1 muscle samples. Both the interaction and the activity are abolished
in the presence of competing GST-Lyn/SH3 domain
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Figure 6 In 15-day-differentiated DM1 myotubes, nuclear MBNL142–43 isoforms are associated with increased presence and activity of Lyn in the nuclei. (a) RT-PCR
analysis of MBNL1Ex5 and MBNL1DEx5 transcripts in 15-day-differentiated myotubes from three controls and two DM1 patients. (b) Quantification of MBNL1Ex5 transcript
expressed as the percentage of the total MBNL1 transcripts. (c) Representative WB analysis with anti-p-Tyr, anti-Lyn, anti-P9 (against MBNL142–43) of nuclear lysates from
15-day-differentiated myotubes of three controls and two DM1 patients. Equal loading was monitored by anti-Lamin B antibody. (d–f) Quantification of at least three
independent WB analyses as in (c). Values, normalized to the loading control, were expressed as mean±S.D. and compared with controls for statistical evaluation. *Po0.05;
**Po0.02; ***Po0.005 by Mann–Whitney test. (g) Representative confocal images of 15-day-differentiated myotubes, from two controls and two DM1 patients, showing
different localization of MBNL142–43 and Lyn (obtained using identical exposure time and acquisition setting). Myotubes from DM1 patients were also transfected with
siMBNL1-Ex5, designed to target specifically the MBNL142–43 isoforms. Nuclei were labelled with DAPI (blue), MBNL1 with anti-P9 (red) coupled to immunodetection of Lyn
(green). Scale bar 10mm. (h) Quantification of Lyn and MBNL142–43 colocalization in control and DM1 myotubes. Values represent Manders’ overlap coefficient (the fraction of
total fluorescence signal of Lyn overlapping with MBNL142–43 signal), obtained from confocal images of nuclear and perinuclear regions as in (g) and as described in Materials
and Methods section. Statistical significance was evaluated by two-tailed Student’s t-test (n¼ 30 nuclei, *Po0.05). (i) Representative WB analysis with anti-p-Tyr, anti-Lyn
and anti-P9 (against MBNL142–43) antibodies of nuclear lysates from 15-day-differentiated myotubes of two controls and two DM1 patients, transfected with empty vector (M)
and siMBNL1-Ex5 (iRNA). Equal loading was monitored by anti-Lamin B antibody. (j–l) Quantification of two WB analyses as in (i). Values, normalized to the loading control,
were expressed as mean±S.D.
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localization, indicates an important feature for the sequestra-
tion within the foci. To address this issue, we developed novel
anti-MBNL1 antibodies that allow us to discriminate different
MBNL1 isoforms on the basis of the inclusion/exclusion of
sequences encoded by exon 5. We showed that all four
MBNL1 isoforms analyzed can bind to the nuclear foci of
CUG-expanded repeats in DM1 muscle tissue; however,
MBNL142–43 protein levels are increased in the nuclei of DM1
muscle compared with controls.
Our data demonstrate for the first time that MBNL142–43
isoforms are able to interact with SFKs, in particular with Lyn,
which is one of the most ubiquitous members of this class of
Tyr kinases. As MBNL140–41 isoforms cannot form this
complex, it is possible that the amino-acid stretch encoded
by exon 5 enables MBNL1 protein to interact with SFKs,
possibly through a conformational change whereby the PRMs
become available for binding. The MBNL142–43–SFK interac-
tion is also a prerequisite for enhancement of the SFK activity
relative to the basal state, evidencing a strong functional
discrimination between the long and short isoforms of MBNL1
in terms of interaction with SFKs and regulation of their
activity. We also show that MBNL142–43 overexpression
induces the nuclear translocation of Lyn and enhancement
of its catalytic activity, resulting in increased levels of Tyr
phosphorylation of nuclear proteins, which also occurs in
DM1-patient myotubes. These findings are consistent with the
accumulating evidence that SFKs, Lyn in particular, localize to
a variety of intracellular organelles,38–41 in addition to the
plasma membrane42–44 Importantly, the acylation state—
especially the combination of myristate and palmitoylate—of
the N-terminal SH4 domain of SFKs, has been shown to be
critical in directing SFKs to their final location.45,46 However,
recent studies have noted that an additional mechanism
involved in targeting SFKs to cell compartments is the
engagement of the SH3 domain by PRM-bearing proteins.
Examples include p13, a human T-cell leukaemia virus-1
accessory protein with both a C-terminal PRM and a
mitochondrial localization signal; this has been shown to bind
to and carry SFKs into the mitochondria in a cell culture
model.47 Another striking effect is the increase in SFK activity,
with an elevation of Tyr phosphorylation within the specific
compartment in which SFKs operate. We therefore hypothe-
size a mechanism by which the transfer of SFKs to various cell
districts might exert a more general action on cell fate by
modifying the phosphorylation state and the function of
important substrates in the targeted cell compartments. The
nucleus is another organelle to which Lyn has been shown to
localize, with a role in the DNA damage response and cell
cycle control by associating with and/or phosphorylating
critical signalling molecules involved in cell survival and
apoptosis.48–51 Although far from fully elucidated, nuclear
translocation of Lyn seems to depend on the level of its
catalytic activity.52 In our study, MBNL142–43 seem to act as
carriers for Lyn into the nucleus and they boost its catalytic
activity; the effects of phosphorylation on the target proteins
possibly representing an additional pathogenetic pathway in
DM1, as proposed in Figure 7. Of the Tyr-phosphorylated
proteins localized in the nuclei, the ‘RNA-processing’ group
consists predominantly of players involved in transcription and
post-transcriptional events.53 Of the proteins found to be
‘RNA-related’, six were hnRNP (heterogeneous nuclear
ribonucleoparticles), known to complex with hnRNA and to
influence pre-mRNA transcription, processing and export,
ultimately regulating gene expression and RNA processing,
in particular splicing and alternative splicing. In this scenario,
phosphorylation of pre-mRNA splicing factors may either
cause their removal from pre-mRNA processing events
or result in changing the selection of a splice site.54,55
Figure 7 Additional molecular pathogenetic mechanisms in DM1. Results suggest an additional altered mechanism in DM1 nuclei, triggered by CUG-containing DMPK
transcripts and mediated by the longer Ex5-MBNL142–43 protein isoforms: Tyr hyperphosphorylation of nuclear proteins may influence and mediate changes in gene
expression and RNA processing, expanding the known mechanisms of RNA toxicity in DM1 cells
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The relationship between members of the Src family and
splicing regulators has already been demonstrated and may
coordinate and regulate apoptosis, thus promoting cell
proliferation and formation of metastasis.56 Possibly, the
phosphorylation of splicing regulators, mediated by MBNL142–43
overexpression and SFK activation, allows the cells to lower
temporarily their active concentration, further aggravating the
DM spliceopathy, resulting from the MBNL1 sequestration
into the nuclear foci. Therefore, the altered pattern of MBNL1
expression may further contribute to the multisystemic
manifestation of DM not only through the mere loss-of-
function due to the titration of the RNA-binding proteins by the
CUG expansions. The importance of these data is under-
scored by the ongoing research for functional differences
between the MBNL1 isoforms, which, when better delineated,
would open up the possibility that the MBNL1 proteins may
have different, still unexplored functional roles. A recent paper
by Wang et al.57 suggests that MBNL proteins, besides
regulating the splicing, also contribute to mRNA translation,
protein secretion and localization of alternative 30-UTR
isoforms.57 Our results broaden this scenario showing for the
first time that MBNL142–43 proteins, overexpressed in the DM
muscle, are Lyn-interacting partners that have an important
role in regulating the nuclear-cytoplasmic shuttling and catalytic
activity of Lyn itself, and suggest Lyn as a novel factor
implicated in the onset and progression of DM1. In this respect,
additional functional studies should help clarifying how the
altered Lyn-dependent signalling pathways are affected by the
dysregulation of Lyn itself, thereby paving the way for discovery
of potential novel targets of therapeutic interest in DM1 muscle.
Materials and Methods
Skeletal muscle biopsies. After written consent, DM1 (n¼ 8) muscle
samples were obtained from vastus lateralis by diagnostic open biopsies. Control
samples (also from vastus lateralis, n¼ 4) were obtained from subjects deemed
free of neuromuscular disorders. Molecular diagnosis of DM1, using a combination
of long PCR and Southern blot analysis in the peripheral blood, showed that DM1
patients considered in this study had a CTG expansion between 800 and 1500
repetitions.58
RNA extraction, RT-PCR and QRT-PCR analysis. Total RNA was
extracted from frozen muscle biopsies and 1 mg of total RNA was reverse-
transcribed according to the protocol of the High Capacity cDNA Archive kit
(Applied Biosystem, Foster City, CA, USA). To assess the complete MBNL1
splicing pattern of muscle samples, PCR was performed using primers
corresponding to sequences in exons 2 and 10 of the gene (numbered according
to Pascual et al.;19 for primer sequences see Supplementary Table 1). The
MBNL1 isoform expression levels were measured by SYBR Green semiquanti-
tative QRT-PCR (Applied Biosystems) using primer pairs designed to amplify
MBNL1 exons 4, 5 and 7 to distinguish MBNL140––41 from MBNL142–43.
(Supplementary Table 1). The splicing pattern of the MBNL1 gene across exon 5
in DM1 myoblasts and myotubes has been determined as described previously.14
Transcripts from the exogenous IR and c-TNT minigenes have been measured
using primers representing unique sequences in the cloning vectors
(Supplementary Table 1).
Cloning of MBNL1 isoforms, molecular constructs and MBNL1
recombinant proteins. To clone the sequences of the MBNL140–41–42–43
isoforms, the entire coding sequence of the MBNL1 gene was amplified using the
primers MBNL1-F and MBNL1-R listed in Supplementary Table 1. After sequencing,
PCR products were cloned into pEF1-Myc/HisA and pEF4-V5/HisA (Invitrogen
Carlsbad, CA, USA). Minigene B and minigene RTB300 have been described
previously.21,22 MBNL1 recombinant proteins have been produced in Escherichia coli
and purified as described in the Supplementary Experimental Procedures.
Cell culture and plasmid transfection. Primary myoblasts were
obtained and differentiated as described previously.36 Cells, plated 24 h before
transfection at 80–90% confluence, were transiently transfected with 4 mg of
plasmid DNA and Lipofectamine 2000 (Invitrogen). For siRNA experiments,
myotubes from DM1 patients were transfected with 50 nM of siMBNL1-Ex5 and
analyzed after 48 h. Rhabdomyosarcoma clones with permanent overexpression
of MBNL141 and MBNL143 isoforms, named RD41 and RD43, respectively, were
selected with G418.
Immunofluorescence analysis and RNA fluorescent in situ
hybridization. Lyn and different MBNL1 isoforms were localized as detailed
in the Supplementary Experimental Procedures. CUG-containing foci were
detected in muscle sections and myoblasts as described.36 Colocalization was
evaluated with JACoP plugin59 for the ImageJ software by calculating Manders’
overlap coefficients M1 (fraction of A overlapping B) and M2 (fraction of B
overlapping A). Threshold was arbitrarily set to non-saturating levels for Lyn and
MBNL, whereas it was left saturated for 40,6-diamidino-2-phenylindole (DAPI)
images. Sets of seven M1 and M2 coefficients per pairwise analysis were collected
by increasing the threshold. At least three different images were used for each
condition. Data are shown as mean±S.E.M.
Anti-P9 and anti-P11 antibodies: generation, immunoblotting
and immunoprecipitation. MBNL1 antibodies were raised in rabbits
against amino acids 270–288 (TQSAVKSLKRPLEATFDL; this epitope is encoded
by exon 5 of MBNL1 gene), hereafter defined as P9, and 294–308
(LPPLPKRPALEKTNG, encoded by exon 6 of MBNL1 gene), hereafter defined
as P11, of the human MBNL143 protein (Supplementary Material and
Supplementary Figure S1A) with an extra cysteine at the C terminus. Peptide
synthesis, rabbit immunization and purification of anti-MBNL1 antisera and use of
antibodies in immunoblotting and immunoprecipitation experiments are described
in detail in the Supplementary Experimental Procedures.
Surface plasmon resonance. The interaction between MBNL1 isoforms
and Lyn was performed as described below. Recombinant MBNL1 isoforms were
immobilized on channels 1 and 3 of a His Cap research-grade sensor chip
(Nomadics, ICx Nomadics Bioinstrumentation, Group, Oklahoma City, OK, USA)
by nickel-affinity interaction using the manufacturer’s protocols. Channel 2 was
used as reference for all experiments. The Lyn kinase SH3 domain was the
analyte and it was injected at 30 ml/min. SPR measurements were carried out in
HBS buffer with 0.005% P20 surfactant at 20 1C using a SensiQ Pioneer
Instrument (ICx Technologies, Stillwater, OK, USA). The data were analyzed with
the Qdat evaluation analysis software (ICx Nomadics Bioinstrumentation, Group).
Phosphorylation and interaction assays. Tyr kinase assays were
performed in 40ml reaction mixture containing 50 mM Tris/HCl, pH 7.5, 10 mM
MnCl2, 30mM ATP/[g-
33P]ATP (specific activity 1000 c.p.m./pmol) (Perkin-Elmer,
Waltham, MA, USA), 100mM sodium orthovanadate, 200mM Src-specific peptide
substrate cdc2(6–20) as substrate and 20 ng of Src, or Lyn. Following incubation
for 5 min at 30 1C, the reaction was blocked by adding 5 SDS buffer and the
samples were subjected to SDS-PAGE. Peptide phosphorylation was evaluated
using the Cyclone Plus Storage Phosphor System (Perkin-Elmer). In time-course
experiments, MBNL140–41 and MBNL142–43 (each 1 mM) were phosphorylated in
the reaction mixture and the reactions were stopped at different time points as
indicated above. The degree of protein phosphorylation was evaluated by analysis
on the Cyclone Plus Storage Phosphor System (Perkin-Elmer). Interaction assay
(between MBNL1 isoforms and Lyn) followed by immunoprecipitation were
performed as described in the Supplementary Experimental Procedures.
Statistical analysis. Statistical analysis was performed only where three or
more experimental values were available. Quantitative data were presented as
mean±S.D. The statistical comparisons were performed using Mann–Whitney
and Kruskal–Wallis tests, for comparison between two or more groups,
respectively. In every analysis, values of Po0.05 were considered significant.
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